The positive CHMP opinion for upadacitinib is based on results from two induction studies and one maintenance study1-4
Crohn's disease is a chronic, systemic disease that manifests as inflammation within the gastrointestinal tract, causing persistent diarrhea and abdominal pain5,6
If approved by the European Commission (EC), this will be the seventh indication for upadacitinib in the European Union (EU), and the first JAK inhibitor for Crohn's disease, adding to AbbVie's gastroenterology portfolio
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.